MERZ-AESTHETICS
31.3.2022 09:02:11 CEST | Business Wire | Press release
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 20th Aesthetic & Anti-Aging Medicine World Congress (AMWC), with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diverse society. AMWC 2022, held from Thursday, 31 March to Saturday, 02 April 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Monaco and/or virtually. Merz Aesthetics is an elite sponsor of the global industry congress.
“As part of our continued commitment to the aesthetic medicine industry, we are looking forward to reunite with partners and experts, share insights and foster scientific exchange in the aesthetics field at this year’s AMWC congress,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We are focused to advance science in aesthetics, fuel confidence and empower unique attitudes.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs – by fueling confidence and empowering unique attitudes.
Merz Aesthetics is organizing an expert program led by esteemed medical aesthetic experts and presenting new data throughout the course of the meeting.
Expert Keynote Sessions
Merz Aesthetics is organizing expert-led keynote sessions to be held on Thursday, 31 March – Friday, 01 April (via registration only).
- “Skin Glow and Skin Quality – optimizing your skin boosting treatment” – Dr. Sonja Sattler, Thursday, 31 March, 10:00-12:00h CEST.
- “Collagen Expert Class – insights into collagen stimulation, skin quality and patient safety” – Dr. Jani van Loghem, Thursday, 31 March, 13:00-15:00h CEST.
- “Optimizing the Patient Journey in the Digital Age” – Adam Haroun, Thursday, 31 March, 15:30-17:00h CEST.
- “Aesthetic Toxin Expert Talk – purity and precision for long-term patient satisfaction” – Dr. Carla Pecora, Friday 01 April, 10:00-12:00h CEST.
- “Skin Lifting – the expert approach to customized treatments” – Dr. Tatjana Pavicic, Friday 01 April, 13:00-15:00h CEST.
- “All About Lips – expert techniques to address the unique needs of patients” – Dr. Kate Goldie, Friday 01 April, 15:30 – 17:30h CEST
Oral Presentations
Dr. Carla Pecora: ‘Clinical experience with intradermal microdroplet injection of diluted Incobotulinum toxin A for facial flushing and pore size improvement’ (Neuromodulators); Saturday, 02 April, 9:00h CEST, Nijinski
Dr. Carla Pecora: ‘A combination approach using IncobotulinumtoxinA and CPM-HA injections for the periorbital complex improvement.’ (Periorbital Zone and “Foxy Eyes” Trend – Lifting & Rejuvenating); Saturday, 02 April, 11:15h CEST, Salle des Princes & AMWC Stream 1
E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A LONGitudinal evaluation and Real-world evidence of Uniquely purified incobotulinumtoxinA in treatment naïve participants. Andy Curry, Merz Aesthetics - USA, Terrence Keaney, MD – USA, Niamh Corduff, MD – Australia, Simon Ravichandran, MD – UK, Ada Trindade, MD – Brasil.
- Chemobioresurfacing: Does intradermal injection of botulinumtoxinA plus hyaluronic acid improve skin quality? Diane Duncan, MD – USA.
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- The local tissue lifting capacity of dermal filler is greater with increasing hyaluronic acid concentration using an ex vivo human skin model. Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Thomas Hengl – all Merz Aesthetics, Germany.
- Distance between calcium hydroxylapatite microspheres is essential for fibroblast invasion and resulting neocollagenesis. Bartosch Nowag, Nils Warfving, Thomas Hengl – all Merz Aesthetics, Germany.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Yana Yutskovskaya, MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com .
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 15:10:00 CET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release
Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release
Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom